YM BioSciences Inc. (YMI)
-NYSE MKT 2.94 0.00(0.00%) Feb 8, 4:01PM EST
| Prev Close: | 2.94 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.45 - 2.95 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 3,613,880 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Large Market Opportunity in HCV Space Due to Unmet Medical Need, Large Reservoir of Patients and Current Standard of CareWall Street Transcript(Fri, Apr 26)
- Under-the-Radar Hedge Fund Focusing on Pharmaat Motley Fool(Wed, Mar 20)
- Gilead Sciences Completes Acquisition of YM BioSciencesBusiness Wire(Fri, Feb 8)
- Gilead Sciences completes acquisition of YM BioSciencesPR Newswire(Fri, Feb 8)
- Gilead Sciences completes acquisition of YM BioSciencesCNW Group(Fri, Feb 8)
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013CNW Group(Thu, Feb 7)
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013PR Newswire(Thu, Feb 7)
- Gilead CEO John Martin wins 2012 bonus of $3.4 millionat bizjournals.com(Tue, Feb 5)
- YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead SciencesCNW Group(Tue, Feb 5)
- YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead SciencesPR Newswire(Tue, Feb 5)
- YM BioSciences Shareholders Approve Plan of Arrangement with Gilead SciencesCNW Group(Thu, Jan 31)
- YM BioSciences Shareholders Approve Plan of Arrangement with Gilead SciencesPR Newswire(Thu, Jan 31)
- 4 Merger and Acquisitions Stock Stories for Investor Pleasureat Wall St. Cheat Sheet(Wed, Jan 23)
- Biotech Industry Expected to Experience More M&A Activity in 2013Marketwired(Mon, Jan 21)
- Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunityat Seeking Alpha(Fri, Jan 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
YM BioSciences Inc., a drug development company, engages in developing hematology and cancer-related products. Its products include CYT387, a dual inhibitor of the JAK1 and JAK2 kinases, which has implicated in a family of hematological conditions...
View More 
0.73%